Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Sep 21, 2020- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology- MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip's history as a safe and effective treatment option
Sep 17, 2020- Abbott's Libre Sense Glucose Sport Biosensor, with CE Mark, is built upon the company's world-leading continuous glucose monitoring technology- Abbott is collaborating with sports performance technology company Supersapiens to advance this first-of-its-kind product- As part of an observational trial, two cycling teams leading into the world's largest annual sporting event, the Tour de France, trained with Abbott's Libre Sense biosensor to track the correlation between glucose levels and their athletic performance- Sep 3, 2020- The LIFE-BTK trial will evaluate the company's new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK)- Esprit BTK was granted breakthrough device designation by the U.S. FDA- There are no stents or drug-coated balloons currently approved for use below the knee in the U.S.